DAS28 Score Calculator
Quantifies rheumatoid arthritis disease activity using a 28-joint assessment, inflammatory markers (ESR or CRP), and patient global assessment. The primary outcome measure for treat-to-target strategies and EULAR response criteria.
Calculate DAS28 Score
Select the inflammatory marker variant, then complete the 28-joint assessment, lab value, and patient global assessment. Tap each joint button to cycle through: none → tender → swollen → both → none. An optional previous DAS28 allows EULAR response calculation.
The DAS28 assesses 28 specific joints and does not include the feet, ankles, hips, or thoracolumbar spine. Clinically significant disease activity in these excluded sites may not be reflected in the DAS28 score. Always complement the DAS28 with a complete clinical assessment, particularly when the score appears discordant with the patient’s functional status.
Understanding the DAS28
The Disease Activity Score using 28 joints (DAS28) was developed by van der Heijde and colleagues from the University of Nijmegen in the early 1990s as a simplified version of the original DAS44. It has become the most widely used composite disease activity measure in rheumatoid arthritis, adopted by EULAR, ACR, and most national rheumatology societies for clinical trials and routine practice.
The DAS28 integrates four components — a 28-joint tender count, a 28-joint swollen count, an acute-phase reactant (ESR or CRP), and a patient global assessment of disease activity — into a single continuous score that ranges from 0 to approximately 9.4. This composite approach captures both the objective inflammatory burden and the patient’s subjective experience of disease.
DAS28-ESR Formula
DAS28-ESR =
0.56 × √(TJC28)
+ 0.28 × √(SJC28)
+ 0.70 × ln(ESR)
+ 0.014 × PGA
TJC = tender joint count (0–28)
SJC = swollen joint count (0–28)
ESR = mm/hr (minimum 1)
PGA = patient global VAS 0–100 mm
DAS28-CRP Formula
DAS28-CRP =
0.56 × √(TJC28)
+ 0.28 × √(SJC28)
+ 0.36 × ln(CRP + 1)
+ 0.014 × PGA
+ 0.96
CRP in mg/L (minimum 0)
The +0.96 constant and different ln coefficient adjust for the differing scale and kinetics of CRP compared to ESR.
Key distinction — ESR vs CRP: DAS28-ESR and DAS28-CRP are not interchangeable. The CRP variant tends to produce slightly lower scores and classifies more patients in remission compared to the ESR variant. This is clinically important — a patient may achieve “remission” by DAS28-CRP but not DAS28-ESR. Be consistent: use the same variant for longitudinal monitoring in individual patients.
Interpretation & EULAR Response Criteria
| DAS28 Value | Disease Activity | Clinical Implication |
|---|---|---|
| < 2.6 | Remission | Treatment target achieved; consider maintaining current therapy |
| 2.6 – < 3.2 | Low Disease Activity | Acceptable alternative target; treatment escalation may not be needed |
| 3.2 – 5.1 | Moderate Disease Activity | Consider treatment escalation per treat-to-target protocol |
| > 5.1 | High Disease Activity | Treatment escalation is recommended; reassess within 1–3 months |
EULAR Response Criteria
The EULAR response classifies treatment response by combining the change in DAS28 from baseline with the current DAS28 value achieved:
| DAS28 Improvement | Current DAS28 ≤ 3.2 | Current DAS28 3.2–5.1 | Current DAS28 > 5.1 |
|---|---|---|---|
| > 1.2 | Good | Moderate | Moderate |
| 0.6 – 1.2 | Moderate | Moderate | None |
| ≤ 0.6 | None | None | None |
DAS28 remission (< 2.6) has been criticised for being achievable even with several swollen joints if the ESR/CRP and PGA are low. The ACR/EULAR Boolean remission criteria (TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dL, PGA ≤ 1/10) are more stringent and are increasingly recommended as the primary remission target in clinical practice and trials.
Clinical Details & Treat-to-Target
The treat-to-target (T2T) approach — endorsed by EULAR, ACR, and most international guidelines — uses the DAS28 (or an equivalent composite measure) as the primary outcome to guide sequential treatment escalation. The core principles are:
- Set a target: Remission (DAS28 < 2.6) is the primary target. Low disease activity (DAS28 < 3.2) is an acceptable alternative in patients with long-standing disease or comorbidities that limit treatment options.
- Measure regularly: Assess DAS28 every 1–3 months during active disease.
- Escalate if not at target: If the target is not reached within 3 months (or significant improvement not seen by 6 months), escalate treatment — add or switch DMARD, add biologic or targeted synthetic DMARD.
- Maintain once at target: Once remission or low disease activity is sustained for ≥ 6 months, consider cautious dose reduction (but not discontinuation) of biologics.
T2T has been shown to produce better radiographic, functional, and patient-reported outcomes compared to conventional management without systematic monitoring.
The DAS28 joint count is performed bilaterally on the following joints (14 per side, 28 total):
- Shoulders (2) — glenohumeral joint
- Elbows (2)
- Wrists (2)
- Metacarpophalangeal joints (MCP) 1–5 (10 total)
- Proximal interphalangeal joints (PIP) 1–5 (10 total) — includes thumb IP
- Knees (2)
Excluded joints: The DAS28 does not assess the hips, ankles, feet (MTP joints), distal interphalangeal joints (DIP), or the spine. This is a known limitation — patients with significant foot or ankle disease may have a misleadingly low DAS28. The DAS44 and CDAI are alternatives that include additional joints.
Assessment technique: Tenderness is assessed by firm pressure over the joint margin (sufficient to blanch the examiner’s nail bed). Swelling is assessed by palpation for synovial thickening or effusion — bony enlargement alone does not count as swelling.
EULAR 2022 guidelines recommend a phased treatment approach guided by DAS28 or an equivalent composite measure:
- Phase 1 — csDMARD monotherapy: Methotrexate first-line (target dose 25 mg/week), with short-term bridging glucocorticoids (≤ 3 months). If methotrexate is contraindicated, use leflunomide or sulfasalazine.
- Phase 2 — csDMARD combination or first biologic/tsDMARD: If the target is not reached with methotrexate by 3–6 months, options include adding a second csDMARD (e.g., sulfasalazine + hydroxychloroquine), or — particularly if poor prognostic factors are present (high DAS28, seropositive, early erosions) — adding a biologic DMARD (TNF inhibitor, IL-6 inhibitor, T-cell co-stimulation inhibitor, or B-cell depleting agent) or a JAK inhibitor.
- Phase 3 — Switch biologic/tsDMARD: If first biologic fails, switch mechanism of action or try a second agent within the same class.
Poor prognostic factors that support earlier escalation include: high DAS28 (> 5.1), seropositivity (RF and/or ACPA), early erosive disease, high acute-phase reactants, and failure of ≥ 2 csDMARDs.
While DAS28 is the most established composite measure, several alternatives are used in clinical practice and trials:
- CDAI (Clinical Disease Activity Index): TJC28 + SJC28 + PGA (cm) + physician global (cm). No lab required — can be calculated at the bedside. Remission < 2.8, low ≤ 10, moderate ≤ 22, high > 22.
- SDAI (Simplified Disease Activity Index): CDAI + CRP (mg/dL). Adds a lab component. Remission ≤ 3.3, low ≤ 11, moderate ≤ 26, high > 26.
- Boolean remission (ACR/EULAR 2011): TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dL, PGA ≤ 1 (0–10 scale). The most stringent remission definition; increasingly preferred over DAS28 remission for clinical trials.
- DAS44: Original DAS using 44 joints (includes feet). Less commonly used today but captures foot and ankle disease.
In practice, consistency matters more than the specific tool chosen — use the same measure across visits for a given patient.
Special Populations & Considerations
Subclinical synovitis: Musculoskeletal ultrasound can detect synovitis (power Doppler signal) in patients who are in DAS28 remission. Studies suggest that approximately 30–50% of patients in DAS28 remission have ultrasound evidence of residual synovitis. The clinical significance of this “imaging remission gap” is actively debated — it may predict radiographic progression and flare, but treating to ultrasound remission has not yet been proven superior to treating to clinical remission alone.
Common Pitfalls & Limitations
DAS28-ESR and DAS28-CRP produce different numerical scores for the same patient at the same time point. DAS28-CRP tends to give lower scores and classifies more patients in remission. Switching between variants across visits will produce artefactual fluctuations in the DAS28 trend that do not reflect true changes in disease activity. For EULAR response calculation, both the baseline and follow-up DAS28 must use the same variant.
Choose one variant at baseline and use it consistently throughout the patient’s follow-up. Document which variant is being used in the medical record.
The DAS28 gives substantial weight to the tender joint count (coefficient 0.56) and patient global assessment (coefficient 0.014 × 0–100). Both components are subjective and can be elevated by non-inflammatory conditions such as fibromyalgia, generalised pain syndromes, or co-existing osteoarthritis. This leads to a high DAS28 that does not reflect RA inflammatory activity.
Red flags for non-RA driven DAS28 elevation include: TJC significantly exceeding SJC (e.g., TJC 18, SJC 2), high PGA with normal inflammatory markers, widespread non-articular tenderness on examination, and failure to respond to escalating immunosuppression. When suspected, rely more heavily on the SJC and CRP/ESR components, and consider CDAI or SDAI which give less weight to the tender count relative to the swollen count.
It is mathematically possible to achieve a DAS28 < 2.6 (remission) with up to 3–4 swollen joints if the ESR/CRP and PGA are very low. This creates a “remission paradox” where patients are classified as being in remission despite having objective evidence of active synovitis. Studies have shown that residual swollen joints in DAS28 remission predict future radiographic progression.
To address this, the ACR/EULAR Boolean remission criteria (TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dL, PGA ≤ 1) provide a more stringent remission definition that eliminates this possibility. Where possible, aim for Boolean remission rather than DAS28 remission alone, particularly in early RA where preventing structural damage is paramount.
Inter-rater variability in joint counts is a well-recognised source of measurement error in the DAS28. The tender joint count, in particular, is highly examiner-dependent — it varies with the pressure applied, the patient’s pain threshold, and the examiner’s interpretation. Studies show that inter-observer agreement for the TJC is lower than for the SJC.
To minimise variability: standardise the examination technique (firm pressure over the joint margin, blanching the examiner’s nail), have the same examiner assess the patient longitudinally when possible, and consider training sessions to calibrate joint counting across clinicians in multi-assessor clinics.
The DAS28 excludes the feet (MTP joints 1–5), ankles, hips, and spine. The MTP joints are among the most frequently affected in early RA and can harbour significant synovitis that is completely invisible to the DAS28. A patient can have 10 actively swollen MTP joints and a DAS28 of 0 if the 28 assessed joints are unaffected.
Always perform a full joint examination at least at baseline and periodically thereafter, regardless of the DAS28 result. The squeeze test across the MTP joints is a quick screening manoeuvre for forefoot synovitis. If foot or ankle disease is prominent, consider using the DAS44, ultrasound assessment, or simply documenting the additional affected joints alongside the DAS28.
Quick Reference Summary
| Component | Range | Coefficient (ESR) | Coefficient (CRP) |
|---|---|---|---|
| TJC28 | 0–28 | 0.56 × √TJC | 0.56 × √TJC |
| SJC28 | 0–28 | 0.28 × √SJC | 0.28 × √SJC |
| ESR / CRP | ESR: mm/hr · CRP: mg/L | 0.70 × ln(ESR) | 0.36 × ln(CRP+1) |
| PGA | 0–100 mm VAS | 0.014 × PGA | 0.014 × PGA + 0.96 |
Treat to target: aim for DAS28 remission (< 2.6) or at minimum low disease activity (< 3.2). Measure every 1–3 months. Escalate treatment if the target is not reached within 3–6 months. Be consistent — use the same DAS28 variant (ESR or CRP) at every visit for the same patient.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Prevoo ML, van ‘t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum. 1995;38(1):44–48. DOI: 10.1002/art.1780380107
- Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745–757. DOI: 10.1016/j.rdc.2009.10.001
- Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954–960. DOI: 10.1136/ard.2007.084459
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. DOI: 10.1136/ard-2022-223356
- Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15. DOI: 10.1136/annrheumdis-2015-207524
- Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404–413. DOI: 10.1136/ard.2011.149765
- Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796–806. DOI: 10.1186/ar1740
- van der Heijde DM, van ‘t Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916–920. DOI: 10.1136/ard.49.11.916
- Inanc N, Ozen G, Direskeneli H, et al. Discordance of DAS28 with clinical remission criteria reflects residual disease activity. Clin Exp Rheumatol. 2021;39(6):1352–1357. DOI: 10.55563/clinexprheumatol/p4q9x9